Skip to main content
Clinical Trials/TCTR20170827002
TCTR20170827002
Completed
Phase 4

The effect of selenium supplementation in moderate-to-severe thyroid eye disease patients : a randomized-placebo controlled trial

The Ratchadapiseksompotch Fund, Faculty of Medicine0 sites46 target enrollmentAugust 27, 2017

Overview

Phase
Phase 4
Intervention
Not specified
Conditions
Moderate-to-severe thyroid eye disease patients
Sponsor
The Ratchadapiseksompotch Fund, Faculty of Medicine
Enrollment
46
Status
Completed
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
August 27, 2017
End Date
April 30, 2021
Last Updated
last year
Study Type
Interventional
Sex
All

Investigators

Sponsor
The Ratchadapiseksompotch Fund, Faculty of Medicine

Eligibility Criteria

Inclusion Criteria

  • 1\.The patients who have been categorized into moderate\-to\-severe thyroid eye disease group according to EUGOGO recommendation.
  • 2\. Age above 18 years old
  • 3\. The patients with normal thyroid hormone level (FT4, FT3\) for at least 6 months
  • 4\. The patients who presented with thyroid eye symptoms of less than 18 months.

Exclusion Criteria

  • 1\. The patients who have history of allergic reaction to selenium
  • 2\. The patients who previously took or who are currently taking selenium supplement.
  • 3\. The patients who are pregnant or breast\-feeding.

Outcomes

Primary Outcomes

Not specified

Similar Trials